A photo of Lauren Pommert.

Lauren P. Pommert, MD, MS


  • Pediatric Oncologist, Leukemia/Lymphoma Program, Cancer and Blood Diseases Institute
  • Assistant Professor, UC Department of Pediatrics
My goal is to provide compassionate, cutting-edge cancer treatment, symptom management and psychological support to both my patients and their families, because the diagnosis of childhood cancer and its treatments effect the entire family.
Lauren P. Pommert, MD, MS

About

Biography

As a pediatric oncologist, I specialize in the care of children, adolescents and young adults with hematologic malignancies and lymphoma, particularly those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML), Hodgkin lymphoma and non-Hodgkin lymphoma. My specific interest is in caring for patients with AML, relapsed or refractory AML, and in using comprehensive leukemia genetic data to aid in therapy selection.

Since I was a young child, I have always wanted to follow in my father's footsteps and become a physician. I enjoy taking care of patients with complex conditions across various locations in the hospital — from the outpatient clinic to the intensive care unit. I am fortunate to have the opportunity to form long-lasting relationships with patients and their families and to help them through their cancer journey and into survivorship.

Part of what drew me to oncology is the ability to care for the patient as a whole. My goal is to provide compassionate, cutting-edge cancer treatment, symptom management and psychological support to both my patients and their families, because the diagnosis of childhood cancer and its treatments effect the entire family. I strive to involve many specialized team members to provide comprehensive care and ensure the best possible quality of life while patients are on their treatment journey and after its completion.

I’ve received the following awards and recognitions:

  • John H. Gladney, MD Diversity Award, Saint Louis University School of Medicine, 2013
  • Rodney M. Coe Distinction in Community Service Award, Saint Louis University School of Medicine, 2013
  • Arthur E. McElfresh Award in Pediatrics, Department of Pediatrics, Saint Louis University School of Medicine, 2013
  • Award for Excellence in Critical Care, Department of Pediatrics, Saint Louis University School of Medicine, 2016
  • Chief Fellow, Division of Hematology, Oncology and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI, 2018
  • First Place, 13th Annual Medical College of Wisconsin Fellow Research Day, 2019

With my research, I am trying to improve survival outcomes for patients with relapsed and refractory acute myeloid leukemia through the clinical investigation of novel therapeutic agents and new combinations of therapeutic agents. In addition to improving survival, I am also interested in decreasing the long-term toxicities associated with our current therapies.

I enjoy spending my free time outdoors with my family as well as cooking and cycling.

MD: Saint Louis University School of Medicine, Saint Louis, MO.

Residency: Saint Louis University School of Medicine, Saint Louis, MO.

Fellowship: Medical College of Wisconsin, Milwaukee, WI.

MS: Clinical and Translational Science, Medical College of Wisconsin, Milwaukee, WI.

Certification: Pediatrics, 2016.

Interests

Acute myeloid leukemia; relapsed and refractory acute myeloid leukemia; high-risk and relapsed acute lymphoblastic leukemia; lymphoma

Services and Specialties

Leukemia Lymphoma

Interests

Novel therapeutics for relapsed and refractory acute myeloid leukemia; immunotherapy for acute myeloid leukemia; genetics of acute leukemia; mutational landscape of acute leukemia

Research Areas

Cancer and Blood Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Lymphoid Malignancies in Shwachman-Diamond Syndrome: Incidence, Clinical Features, and Outcomes from the North American SDS Registry. Reed, HD; Do, H; Weller, E; Farrar, JE; Gamper, C; Lau, BW; Pommert, L; Atkinson, I; Joos, M; Loveless, S; et al. Blood. 2023; 142:5662.

Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Taylor, ZL; Miller, TP; Poweleit, EA; DeGroote, NP; Pommert, L; Awoniyi, O; Board, SG; Ugboh, N; Joshi, V; Ambrosino, N; et al. Clinical and Translational Science. 2023; 16:2130-2143.

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Kleman, A; Singavi, A; Pommert, L; Mathison, AJ; Hari, P; Dhakal, B; Mohan, M; Janz, S; Knight, JM; Shah, MV; et al. Blood Advances. 2023; 7:5549-5553.

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Bender, J; Damodharan, S; Moskop, A; Toner, K; Vatsayan, A; Capitini, C; Baggott, C; Schiff, DE; Katsanis, E; Raikar, SS; et al. Journal of Clinical Oncology. 2023; 41:10031.

Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. Gossai, N; Bhojwani, D; Schafer, ES; Chang, BH; Pommert, L; Verma, A; Malvar, J; Chi, YY; Hitzler, J; Burke, MJ; et al. Leukemia. 2023; 37:1138-1140.

Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy. Bender, JD; Rubinstein, JD; Mizukawa, B; Perentesis, JP; Pommert, L. Pediatric Blood and Cancer. 2023; 70:e30214.

The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies. Pommert, L; Tarlock, K. Hematology-American Society of Hematology Education Program. 2022; 2022:603-610.

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial. Lamble, AJ; Chi, Y; Chang, BH; Verma, A; Faulk, KE; Stevens, AM; Pommert, L; Tucker, S; Brookhart, B; Shah, NN; et al. Blood. 2022; 140:6102-6103.

Severe Adverse Events Associated with Concentrations of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia Patients. Miller, TP; DeGroote, NP; Taylor, Z; Pommert, L; Awoniyi, O; Board, S; Ugboh, N; Joshi, V; Weisnicht, A; Ambrosino, N; et al. Blood. 2022; 140:2185-2186.

106 GEMCITABINE, OXALIPLATIN, AND ANTI-CD20 THERAPY IS SAFE AND EFFECTIVE IN CHILDREN AND YOUNG ADULTS WITH NON-HODGKIN LYMPHOMA UNFIT FOR INTENSIVE THERAPY. Bender, J; Rubinstein, J; Pommert, L. Leukemia Research: clinical and laboratory studies. 2022; 121:s63-s64.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating